% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • kzxc kzxc Sep 21, 2009 1:20 PM Flag

    Don't Forget EPCT's Partner Speaks on 9/21

    excuse my ignorance but what kind of royalty will EPCT get on Azixa sales?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The royalty is on net sales. The first royalty rate is a single figure between 5-9 and there is a double figure after certain levels of sales.

      Sources: Myriad before split, and old releases from Epicept.

    • The royaly rate is not disclosed, but here is what the company website says:

      EpiCept is a licensor to Myriad Genetics, Inc. for the exclusive worldwide right to develop and commercialize the MX90745 series of apoptosis inducers. Under the terms of the agreement, Myriad is responsible for all clinical development and commercialization of compounds from this series. Myriad has initiated clinical trials for Azixa™* (MPC-6827), for the treatment of brain cancer and other solid tumors. The agreement requires that Myriad make licensing, research and milestone payments to EpiCept, assuming the successful commercialization of a compound for the treatment of cancer, as well as pay a royalty on product sales. The Company is eligible to receive up to $27 million in milestone payments from Myriad for the development of Azixa.

0.42-0.01(-2.33%)Feb 5 3:59 PMEST